Acer Therapeutics Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | — | $1.3M | $0 | — | — | — |
| Operating income | −$24.6M | −$15.9M | −$22.8M | −$29.9M | −$21.7M | −$13.9M |
| Net income | −$26.2M | −$15.4M | −$22.9M | −$29.4M | −$21.3M | −$14.2M |
| Total assets | $11.6M | $36.3M | $14.6M | $21.5M | $50.7M | $24.4M |
| Total liabilities | $28.4M | $38.0M | $6.4M | $3.1M | $5.6M | $2.0M |
| Equity | −$16.8M | −$1.7M | $8.2M | $18.4M | $45.1M | $22.3M |
| EPS (diluted) | $-1.66 | $-1.08 | — | — | — | — |
| Shares out. | 14.3M | 14.3M | 10.1M | 10.1M | 7.5M | 7.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- 156.5%
- Return on assets
- −225.7%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 244.2%
- Debt / equity
- —
- Book value / share
- $-1.17
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -63.03distress
- Accruals / assets
- 34.5%high accruals
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 3 warning● 1 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 14, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2021
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2009
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- OLPRUVADec 22, 2022
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Aselage SteveDirector | Nov 17, 2023 | D | 483,741 | — |
| Dunn John MichaelDirector | Nov 17, 2023 | D | 27,380 | — |
| Joseph DonaldOfficer — See Remarks | Nov 17, 2023 | D | 14,285 | — |
| Schelling ChrisOfficer — PRESIDENT AND CEO | Nov 17, 2023 | D | 2.7M | — |
| Palmin Harry SOfficer — CHIEF FINANCIAL OFFICER | Nov 17, 2023 | D | 125,000 | — |
| Davis Jefferson EOfficer — CHIEF BUSINESS OFFICER | Nov 17, 2023 | D | 71,645 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsNov 20, 2023
- Shareholder vote · Other material eventNov 8, 2023
- Entered a material agreement · Delisting / listing-standard notice · Other material eventNov 2, 2023
- Entered a material agreement · Terminated a material agreement · New financial obligation · Other material eventAug 31, 2023
- Results of operationsAug 14, 2023
- Entered a material agreement · New financial obligation · Regulation FD disclosure · Other material eventJun 26, 2023
- Delisting / listing-standard noticeJun 7, 2023
- Shareholder voteMay 22, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GFORM 15-12GNov 30, 2023
- EFFECTNov 24, 2023
- EFFECTNov 24, 2023
- 4FORM 4 SUBMISSIONNov 20, 2023
- 4FORM 4 SUBMISSIONNov 20, 2023
- 4FORM 4 SUBMISSIONNov 20, 2023
- 4FORM 4 SUBMISSIONNov 20, 2023
- 4FORM 4 SUBMISSIONNov 20, 2023
- 4FORM 4 SUBMISSIONNov 20, 2023
- 10-QNov 20, 2023
- S-8 POSNov 20, 2023
- S-8 POSNov 20, 2023
- S-8 POSNov 20, 2023
- S-8 POSNov 20, 2023
- S-8 POSNov 20, 2023
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.